Trial · NCT03520946
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival | Up to 4 years | Overall survival according to Kaplan-Meier |
| Secondary | Overall response rate (ORR) | Up to 4 years | ORR defined as the proportion of patients with complete or partial remission according to RECIST 1.1 |
| Secondary | Disease control rate (DCR) | Up to 4 years | DCR defined as the proportion of patients with complete or partial remission and stable disease according to RECIST 1.1 |
| Secondary | Progression-free survival (PFS) | Up to 4 years | PFS, defined as the time from enrollment/randomization to the first occurrence of progression, as determined by the investigator using CT criteria, or death from any cause |
| Secondary | Overall survival (OS) rate at different time points | 6 months and 1 year | OS rate at 6 and 12 months, defined as patients who are alive after at 6 and 12 months, respectively |
| Secondary | Efficacy (ORR) subgroup | Up to 4 years | Efficacy (ORR) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1 |
| Secondary | Efficacy (PFS) subgroup | Up to 4 years | Efficacy (PFS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1 |
| Secondary | Efficacy (OS) subgroup | Up to 4 years | Efficacy (OS) in patients who develop neutropenia grade ≥2 (ANC ≤1500/μl) in cycle 1 |
| Secondary | Quality of life I (QoL) | Up to 1 year | Quality of life (QoL) as measured by EORTC-QLQ-C30 at d1 of each cycle and on EOT (end of treatment). |
| Secondary | Quality of life II (QoL) | Up to 1 year | Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT. |
| Other | Explorative: Overall response rate (ORR) | Up to 4 years | ORR according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis |
| Other | Explorative: Overall survival (OS) | Up to 4 years | OS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis |
| Other | Explorative: Progression-free survival (PFS) | Up to 4 years | PFS according to gene expression, mutational profiles, plasma biomarkers and radiologic analysis |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03520946/registered